ISSN: 2468-1253

Journal Home

Journal Guideline

The Lancet Gastroenterology and Hepatology Q1 Unclaimed

Elsevier Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

The Lancet Gastroenterology and Hepatology is a journal indexed in SJR in Gastroenterology and Hepatology with an H index of 105. It has an SJR impact factor of 8,957 and it has a best quartile of Q1. It has an SJR impact factor of 8,957.

The Lancet Gastroenterology and Hepatology focuses its scope in these topics and keywords: bowel, gastrointestinal, hepatitis, chronic, multicentre, extent, infectionfuture, inflammation, exploration, life, ...

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Gastroenterology (Q1) Hepatology (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

The Lancet Gastroenterology and Hepatology

8,957

SJR Impact factor

105

H Index

235

Total Docs (Last Year)

671

Total Docs (3 years)

4964

Total Refs

7447

Total Cites (3 years)

255

Citable Docs (3 years)

9.92

Cites/Doc (2 years)

21.12

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Nature Reviews Gastroenterology and Hepatology Q1
Lancet Gastroenterology and Hepatology, The Q1
Gut Q1
Gastroenterology Q1
Clinical Gastroenterology and Hepatology Q1

Compare this journals

Aims and Scope

Best articles by citations

15th European Crohn's and Colitis Organisation Congress

Resolving gastric cancer aetiology: an update in genetic predisposition

The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment

Treating hepatitis C virus in patients with chronic renal failure

Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission

Hepatitis C incidence 3 years after implementation of an educate, test, and treat programme in an Egyptian village

Beyond the Milan criteria for liver transplantation in children with hepatic tumours

Decision making for liver biopsy in NASH, not so FAST?

Probiotics: elixir or empty promise?

Fermented foods: fad or favourable addition to the diet?

Detection of colorectal adenomas with a real-time computer-aided system (ENDOANGEL): a randomised controlled study

SHOW MORE ARTICLES

My life with achalasia

Hepatitis C treatment and liver cancer recurrence: cause for concern?

Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study

Anti-TNF treatment failure: drug levels, immunogenicity, or both?

Pancreaticobiliary maljunction and congenital biliary dilatation

Examining Britain's "drink problem"

Upper gastrointestinal endoscopy: can we cut the cord?

Eliminating hepatitis C in Europe

Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease

Samuel Gee: the modern era for coeliac disease

Apps: solutions to sociological and health problems

Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study